8-KRegulation FD

ABBOTT LABORATORIES 8-K Report, Regulation FD Disclosure (Oct 17, 2005)

Filed October 17, 2005For Securities:ABT

Summary

This 8-K filing from Abbott Laboratories on October 17, 2005, primarily announces that TAP Pharmaceutical Products Inc., an affiliate of Abbott, received an "approvable letter" from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for febuxostat. Febuxostat is an investigational compound intended for the management of hyperuricemia in patients suffering from gout. The approvable letter indicates that the FDA has tentatively approved the drug, pending the resolution of certain conditions or concerns outlined in the letter. TAP Pharmaceutical Products Inc. expressed confidence in addressing these points to secure final approval in a timely manner. Importantly for investors, Abbott stated that this development has no impact on its previously issued earnings per share (EPS) guidance for the fiscal year 2005. This suggests that the potential market for febuxostat, while significant, was already factored into Abbott's financial projections or that the approval process is not expected to yield immediate material financial results that would alter current guidance. Investors should monitor future communications regarding the final approval status and any commercialization plans for febuxostat.

Key Highlights

  • 1TAP Pharmaceutical Products Inc., an affiliate of Abbott Laboratories, received an "approvable letter" from the FDA for the investigational drug febuxostat.
  • 2Febuxostat is intended for the management of hyperuricemia in patients with gout.
  • 3The FDA's "approvable letter" signifies a tentative approval, with conditions or concerns to be addressed.
  • 4TAP Pharmaceutical Products Inc. is confident in addressing the FDA's requests for final approval.
  • 5The company submitted the NDA for febuxostat in December 2004, based on extensive Phase III studies.
  • 6Abbott Laboratories confirmed that this development has no impact on its previously stated EPS guidance for 2005.
  • 7The information is furnished under Regulation FD and not filed, meaning it's not incorporated into registration statements unless explicitly noted.

Frequently Asked Questions

Febuxostat is an investigational drug for which TAP Pharmaceutical Products Inc. (an affiliate of Abbott Laboratories) received an "approvable letter" from the FDA. Its intended use is for the management of hyperuricemia, a condition characterized by high levels of uric acid in the blood, in patients who suffer from gout.

An "approvable letter" from the FDA indicates that the agency has reviewed the New Drug Application (NDA) and has tentatively decided to approve the drug. However, it also means that there are outstanding issues, conditions, or concerns that the applicant must address to the FDA's satisfaction before final approval is granted. It is not a final approval.

Abbott Laboratories explicitly stated in the filing that this development has no impact on its previously announced earnings per share (EPS) guidance for the fiscal year 2005. This suggests that the potential financial impact of febuxostat was either already incorporated into their forecasts or is not expected to be material to 2005 results.

This information is being furnished under Regulation FD (Fair Disclosure) and is not being filed as a formal part of the 8-K under the standard items. According to the filing, information furnished under Regulation FD is not automatically incorporated by reference into Abbott's registration statements unless specifically stated.